`
`Date: March 2, 2016
`
`Case: Pharmacosmos A/S -v- Luitpold Pharmaceuticals, Inc. (PTAB)
`
`Planet Depos, LLC
`Phone: 888-433-3767
`Fax: 888-503-3767
`Email: transcripts@planetdepos.com
`Internet: www.planetdepos.com
`
`Worldwide Court Reporting | Interpretation | Trial Services
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 1
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
`
`08:47:34
`
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`1
`
` - - - - - - - - - - - - - -x
`
`PHARMACOSMOS A/S, :
`
` Petitioner, :
`
` v. : Case IPR2015-01490
`
`LUITPOLD : (Patent 7,754,702 B2)
`
`PHARMACEUTICALS, INC., : Case IPR2015-01493
`
` Patent Owner. (Patent 8,431,549 B2)
`
` - - - - - - - - - - - - - -x
`
` DEPOSITION OF ROBERT LINHARDT, PH.D.
`
` NEW YORK, NEW YORK
`
` Wednesday, MARCH 2, 2016
`
` 8:58 a.m.
`
` Job No.: 105663
`
` Pages: 1 - 156
`
` Reported By: Nancy Mahoney, RPR/CCR/CLR
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 2
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` Deposition of ROBERT LINHARDT, PH.D., held at
`
`2
`
` the offices of:
`
` BAKER BOTTS LLP
`
` 30 Rockefeller Plaza
`
` New York, New York 10112-4498
`
` 212.408.2674
`
` Pursuant to agreement, before Nancy Mahoney,
`
` CCR/RPR/CLR, Notary Public in and for the State of
`
` New York.
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2
`
`3 4 5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 3
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`3
`
` A P P E A R A N C E S
`
` ON BEHALF OF PETITIONER PHARMACOSMOS:
`
` JENNIFER C. TEMPESTA, ESQUIRE
`
` jennifer.tempesta@bakerbotts.com
`
` CAROLYN PIRRAGLIA, PH.D., ESQUIRE
`
` carolyn.pirraglia@bakerbotts.com
`
` BAKER BOTTS LLP
`
` 30 Rockefeller Plaza
`
` New York, New York 10112-4498
`
` 212.408.267
`
` ON BEHALF OF PATENT OWNER LUITPOLD
`
` PHARMACEUTICALS, INC.:
`
` MICHAEL D. KAMINSKI, ESQUIRE
`
` mkaminsky@foley.com
`
` ASHA NADIPURAM, PH.D., ESQUIRE
`
` anadipuram@foley.com
`
` NATASHA IYER, ESQUIRE
`
` niyer@foley.com
`
` FOLEY & LARDNER LLP
`
` 3000 K Street, N.W.
`
` Washington, DC 20007-5109
`
` 202.672.5490
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 4
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` A P P E A R A N C E S C O N T I N U E D
`
`4
`
` ALSO PRESENT:
`
` Arthur Mann
`
` Toshiaki Yaguchi, Ph.D.
`
` Daiichi Sankyo, Inc.
`
` John Szpara, Videographer
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2 3 4
`
`5 6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 5
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` C O N T E N T S
`
`EXAMINATION OF ROBERT LINHARDT, PH.D. PAGE
`
`By Mr. Kaminski 10
`
`5
`
` E X H I B I T S
`
` (Attached to transcript.)
`
` LINHARDT PAGE
`
` Exhibit 2023 Dextran and Related 29
`
` Polysaccharides from
`
` Sigma-Aldrich
`
` Exhibit 2024 Nomenclature of 58
`
` Carbohydrates,
`
` Recommendations 1996
`
` Exhibit 2025 Annual Meeting of the 65
`
` ACS Committee on
`
` Nomenclature, Terminology
`
` And Symbols
`
` Exhibit 2026 Tandem MS can Distinguish 118
`
` Haluronic Acid from
`
` N-Acetylheparosan
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2
`
`3
`
`4 5 6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 6
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`6
`
` E X H I B I T S C O N T I N U E D
`
` (Attached to transcript.)
`
` LINHARDT PAGE
`
` Exhibit 2027 Production and Chemical 119
`
` Processing of Low Molecular
`
` Weight Heparins
`
` PREVIOUSLY MARKED EXHIBIT
`
` PAGE
`
` Exhibit 1005 (Previously marked.) 10
`
` Declaration of Robert
`
` Linhardt, Patent
`
` 7,754,702
`
` Exhibit 1014 (Previously marked.) 10
`
` Declaration of Robert
`
` Linhardt, Patent
`
` 8,431,549
`
` Exhibit 1009 (Previously marked.) 36
`
` U.S. Patent Office
`
` 3,100,202
`
` Exhibit 1001 (Previously marked.) 53
`
` U.S. Patent 8,431,549
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 7
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` PREVIOUSLY MARKED EXHIBITS CONTINUED PAGE
`
`7
`
` Exhibit 1004 (Previously marked.) 78
`
` Nephron Original Paper
`
` Exhibit 1003 (Previously marked.) 102
`
` U.S. Patent Application
`
` 2003/0232084
`
` Exhibit 1044 (Previously marked.) 115
`
` Morningside Translator
`
` Certification
`
` Exhibit 1035 (Previously marked.) 129
`
` Physico-chemical
`
` properties of the new
`
` generation IV iron
`
` preparations ferumoxytol,
`
` iron isomaltoside 1000
`
` and ferric carboxymaltose
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 8
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` PREVIOUSLY MARKED EXHIBITS CONTINUED PAGE
`
` Exhibit 1047 (Previously marked.) 135
`
`8
`
` Physical and Chemical
`
` Characterization of
`
` Therapeutic Iron Containing
`
` Materials: A Study of
`
` Several Superparamagnetic
`
` Drug Formulations with
`
` The B-FeOOH or Ferrihydrite
`
` Structure
`
` Exhibit 1002 (Previously marked.) 149
`
` U.S. Patent 5,541,158
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 9
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`9
`
` P R O C E E D I N G S
`
` THE VIDEOGRAPHER: We are now going on the
`
` video record. This is the deposition of Dr. Robert
`
` J. Linhardt in the matter of Pharmacosmos A/S versus
`
` Luitpold Pharmaceuticals, Inc. filed in the United
`
` States Patent and Trademark Office, Case No.
`
` 2015-01490 and 2015-0149.
`
` Today is March 2nd, 2016; the time on the
`
` video monitor is 8:58 a.m. My name is John D.
`
` Szpara, I'm your certified legal videographer. I'm
`
` here representing Planet Depos, Maryland. This
`
` deposition is being held at Baker Botts, 30
`
` Rockefeller Plaza, Suite 4340, New York, New York.
`
` The court reporter is Nancy Mahoney representing
`
` Planet Depo.
`
` Will counsel please identify themselves and
`
` who they represent for the record, please.
`
` MR. KAMINSKI: My name is Mike Kaminski.
`
` I'm going to be taking the deposition. With me also
`
` is Asha Nadipuram and Natasha Iyer also with Foley &
`
` Lardner. Also we have from Daiichi Sankyo we have
`
` two representatives; one is Arthur Mann and the other
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`08:53:38
`
`08:56:17
`
`08:58:00
`
`08:58:05
`
`08:58:11
`
`08:58:13
`
`08:58:18
`
`08:58:24
`
`08:58:27
`
`08:58:33
`
`08:58:36
`
`08:58:40
`
`08:58:42
`
`08:58:46
`
`08:58:49
`
`08:58:50
`
`08:58:52
`
`08:58:54
`
`08:58:56
`
`08:58:59
`
`08:59:06
`
`08:59:09
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 10
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` one is Toshiaki Yaguchi.
`
` MS. TEMPESTA: I'm Jennifer Tempesta with
`
` Baker Botts on behalf of Pharmacosmos and the
`
` witness. With me here is today Carolyn Pirraglia
`
` also of Baker Botts.
`
`10
`
`08:59:13
`
`08:59:15
`
`08:59:17
`
`08:59:20
`
`08:59:23
`
` THE VIDEOGRAPHER: The court reporter will
`
`08:59:24
`
` swear in the witness, please.
`
` ROBERT LINHARDT, PH.D.,
`
`08:59:26
`
`08:59:26
`
` after having been first duly sworn or affirmed to
`
` testify to the truth, was examined and
`
` testified as follows:
`
` EXAMINATION BY COUNSEL FOR LUITPOLD MICHAEL
`
` KAMINSKI:
`
` Q Dr. Linhardt, I'd like to show you copies
`
` of two declarations that you signed in this -- in
`
` this matter. One is against the '702 patent and one
`
` is against the '549 patent.
`
`08:59:40
`
`08:59:43
`
`08:59:49
`
`08:59:53
`
` (PREVIOUSLY MARKED Deposition Exhibit 1005
`
` marked for identification and was attached to the
`
` transcript.)
`
` (PREVIOUSLY MARKED Deposition Exhibit 1014
`
` marked for identification and was attached to the
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 11
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` transcript.)
`
` Do you have them in front of you?
`
` A Yes, I do.
`
`11
`
`08:59:57
`
`08:59:57
`
`08:59:59
`
` Q Before you signed these two declarations,
`
`08:59:59
`
` did you read them carefully?
`
` A Yes, I did.
`
`09:00:02
`
`09:00:04
`
` Q Sitting here today, are you aware of any
`
`09:00:05
`
` changes you want to make to either of these two
`
` declarations?
`
` A Yes, I am.
`
`09:00:09
`
`09:00:13
`
`09:00:13
`
` Q Okay. And what would you like to change?
`
`09:00:14
`
` A In the '549 declaration --
`
`09:00:17
`
` Q Okay.
`
` A -- on Page 6, line 6, I found a
`
` typographical error.
`
`09:00:22
`
`09:00:26
`
` Q If you could identify that so that we're
`
`09:00:32
`
` clear.
`
` A I would like to change dextrin,
`
` d-e-x-t-r-i-n, T1 to dextran, d-e-x-t-r-a-n, T1.
`
` Q Okay. Anything else?
`
` A No.
`
` Q So it seems like you read this again
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:00:35
`
`09:00:36
`
`09:00:41
`
`09:00:48
`
`09:00:49
`
`09:00:51
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 12
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`12
`
` carefully before coming today?
`
` A Yes, I did.
`
` Q Are there any additions -- are there any
`
` other mistakes that you saw in either declaration?
`
` A Not -- not that I can see at this time.
`
` Q Okay. Are there any additions you want to
`
` make to the opinions that you've provided in these
`
` two declarations?
`
` A No.
`
` Q Are there any things you want to remove
`
` from either of these?
`
` A No.
`
` Q I'd like to show you lists that you have in
`
` both of your declarations. Let's take a look at the
`
` one starting -- for the '549 starting on Page 2, 3
`
` and 4. Do you see the lists -- lists that --
`
` A List of exhibits, yes.
`
` Q -- lists of documents that you've
`
` considered in formulating your opinion?
`
` A I see them on Page 2 and 3, not on Page 4.
`
` Q Are there any things you want to change
`
` about this list?
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:00:54
`
`09:00:56
`
`09:00:57
`
`09:01:02
`
`09:01:06
`
`09:01:12
`
`09:01:13
`
`09:01:16
`
`09:01:17
`
`09:01:17
`
`09:01:20
`
`09:01:22
`
`09:01:22
`
`09:01:25
`
`09:01:31
`
`09:01:36
`
`09:01:40
`
`09:01:43
`
`09:01:46
`
`09:01:49
`
`09:01:53
`
`09:01:59
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 13
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` A Not that I can see.
`
` Q Is there anything you want to add to this
`
`13
`
` list?
`
` A Not that I could think of.
`
` Q Is there anything else that you considered
`
` in formulating the opinions in this that -- that you
`
` are relying on?
`
` A These exhibits were the things that I
`
` primarily relied on in forming my opinion.
`
` Q Okay. What else did you rely on -- what do
`
` you mean by primarily as opposed to not primarily?
`
` A So -- so I also have some skill as an
`
` expert in this area, so I relied on my understanding
`
` of science.
`
` Q Okay. But with respect to technical
`
` literature, do you consider this list on Pages 2 and
`
` 3 of your declaration for the '549 to be as complete
`
` as you are sitting here today?
`
` A I have read other things. Obviously this
`
` list that I'm looking at right now is not identical
`
` to the list in the '702 patent, and probably not in
`
` the other declaration that's not being considered
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:02:04
`
`09:02:05
`
`09:02:08
`
`09:02:10
`
`09:02:13
`
`09:02:16
`
`09:02:21
`
`09:02:24
`
`09:02:28
`
`09:02:34
`
`09:02:37
`
`09:02:39
`
`09:02:44
`
`09:02:48
`
`09:02:49
`
`09:02:51
`
`09:02:55
`
`09:02:59
`
`09:03:03
`
`09:03:07
`
`09:03:10
`
`09:03:15
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 14
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` today. So I did have other reading materials that
`
` are not listed on this list in the '549 patent on
`
` Page 2 and 3.
`
`14
`
`09:03:17
`
`09:03:22
`
`09:03:26
`
` Q Okay. So for the '549 patent this list is
`
`09:03:26
`
` the most relevant that you're aware of?
`
` A Yes.
`
` Q And I'd like to ask you just the same
`
` questions then for the other one, the '702, and I'd
`
` like to ask you if you could please take a look at
`
` the list that's on -- also on Pages 2 and 3.
`
` A Okay.
`
`09:03:29
`
`09:03:31
`
`09:03:33
`
`09:03:34
`
`09:03:38
`
`09:03:41
`
`09:03:44
`
` Q Is there anything else that you considered
`
`09:03:46
`
` in formulating your opinion, other than what you've
`
` already mentioned, plus the things on this list?
`
` A No, there's not.
`
` Q Is -- is this the most relevant documents
`
` for this particular declaration?
`
` A I believe it is.
`
` Q Okay. Now, you hold a bachelor's in
`
` chemistry. Is that correct?
`
` A Yes, I do.
`
` Q You hold a bachelor's in -- a master's of
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:03:51
`
`09:03:55
`
`09:03:58
`
`09:04:01
`
`09:04:04
`
`09:04:07
`
`09:04:10
`
`09:04:12
`
`09:04:14
`
`09:04:15
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 15
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`15
`
` arts in chemistry?
`
` A Yes, I do.
`
` Q And you have a Ph.D. in chemistry?
`
` A Yes, I do.
`
` Q Now, your Ph.D. thesis was on the mechanism
`
` of diacyl peroxide decomposition, correct?
`
` A Correct.
`
` Q Does that somehow relate to the field of
`
` Heparin activities?
`
` A No, it does not.
`
` Q What does it relate to?
`
` A It relates to fundamental physical organic
`
` chemistry.
`
` Q Okay. What kind of iron carbohydrate
`
` complex experiences have you had in your professional
`
` career?
`
` A I have not published any papers that I know
`
` of in the area of iron carbohydrate chemistry.
`
` Q Have you gotten any research grants on iron
`
` carbohydrate chemistry?
`
` A I have not received any research grants
`
` that I can recall in this area.
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:04:18
`
`09:04:19
`
`09:04:20
`
`09:04:22
`
`09:04:23
`
`09:04:26
`
`09:04:31
`
`09:04:32
`
`09:04:35
`
`09:04:37
`
`09:04:38
`
`09:04:39
`
`09:04:44
`
`09:04:48
`
`09:04:52
`
`09:04:58
`
`09:04:58
`
`09:05:02
`
`09:05:07
`
`09:05:12
`
`09:05:14
`
`09:05:18
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 16
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` Q Have you counseled any graduate students on
`
` research regarding iron carbohydrate complexes?
`
`16
`
` A Yes, I have.
`
` Q And when was that?
`
` A I have some work ongoing in my laboratory
`
` on magnetic nanoparticles and their complex with
`
` Heparin, which is a polysaccharide, a carbohydrate.
`
` Q Okay. And when did this research start,
`
` this nanoparticle research?
`
` A This has been going on for several years.
`
` Q Can you -- since 2011, 2012, if you
`
` could -- even a guess would be okay, just your best
`
` guess.
`
` A My best guess would be three to four years.
`
` Q Have you taught any classes on iron
`
` carbohydrate complexes?
`
` A There's a very specific title for a class,
`
` so I have not taught any classes with a title iron
`
` carbohydrate complexes.
`
` Q Now, your post-doctorate work was in
`
` Heparin, correct?
`
` A I did post-doctoral work in Heparin, yes,
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:05:19
`
`09:05:24
`
`09:05:27
`
`09:05:27
`
`09:05:31
`
`09:05:34
`
`09:05:43
`
`09:05:48
`
`09:05:50
`
`09:05:52
`
`09:05:54
`
`09:05:58
`
`09:06:03
`
`09:06:03
`
`09:06:06
`
`09:06:08
`
`09:06:12
`
`09:06:16
`
`09:06:21
`
`09:06:22
`
`09:06:26
`
`09:06:26
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 17
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`17
`
` but that was not its entirety.
`
` Q Okay. And your work right now in Heparin
`
` seems to be very well known, so congratulations.
`
` A Thank you.
`
` Q I've -- I noticed about a -- something
`
` called a Heparin crisis in 2007, 2008. Can you
`
` briefly summarize what that is.
`
` A Yes. In 2007 the Heparin supply coming
`
` from China was adulterated. There was a contaminant
`
` introduced in the product that resulted in severe
`
` reactions, including anaphylactoid-type reactions in
`
` hundreds of American patients. The crisis suggested
`
` to have resulted in one hundred to two hundred
`
` deaths. That was a crisis in 2007, 2008.
`
` Q Since 2007, 2008, what percentage of your
`
` time has been -- your professional time has been
`
` related to Heparin?
`
` A Since 2007, 2008 I would say probably
`
` three-quarters of my professional time has been
`
` related -- my research professional time has been
`
` related to Heparin.
`
`09:06:30
`
`09:06:32
`
`09:06:34
`
`09:06:39
`
`09:06:39
`
`09:06:41
`
`09:06:45
`
`09:06:47
`
`09:06:54
`
`09:07:02
`
`09:07:07
`
`09:07:14
`
`09:07:20
`
`09:07:25
`
`09:07:28
`
`09:07:32
`
`09:07:36
`
`09:07:40
`
`09:07:46
`
`09:07:49
`
`09:07:52
`
` Q And how about before 2007, 2008, let's say
`
`09:07:54
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 18
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` between the early 2000s?
`
` A Probably this -- roughly the same amount,
`
` about three-quarters.
`
` Q Can we -- I'd like to ask you about your
`
` experience in patents. What -- do you have any
`
` patents on your own?
`
` A Yes, I do.
`
` Q Do you remember approximately how many?
`
`18
`
`09:07:57
`
`09:08:02
`
`09:08:05
`
`09:08:09
`
`09:08:12
`
`09:08:16
`
`09:08:17
`
`09:08:18
`
` A I know how many I've applied for. I don't
`
`09:08:21
`
` know how many have been issued. I don't know how
`
` many are still maintained.
`
` Q How many have you applied for?
`
` A Probably over 50 patents.
`
` Q Okay. When you're preparing the
`
` applications for filing, do you ever interact with
`
` patent attorneys?
`
` A Yes.
`
` Q Do you consider yourself knowledgeable
`
` about patent -- the patent process, at least from --
`
` from a layperson's point of view?
`
` MS. TEMPESTA: Objection, form.
`
` A I certainly have interacted with patent
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:08:24
`
`09:08:28
`
`09:08:29
`
`09:08:31
`
`09:08:37
`
`09:08:38
`
`09:08:42
`
`09:08:44
`
`09:08:45
`
`09:08:48
`
`09:08:51
`
`09:08:53
`
`09:08:57
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 19
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` attorneys, but I depend on their expertise to draft
`
` the patent.
`
`19
`
`09:09:00
`
`09:09:04
`
` Q And what about expert witnessing, have you
`
`09:09:04
`
` ever been an expert witness in any other legal
`
` proceeding?
`
` A Yes, I have.
`
` Q Can you just generally describe your
`
` experiences.
`
`09:09:07
`
`09:09:09
`
`09:09:10
`
`09:09:11
`
`09:09:14
`
` A In the Heparin crisis case I was an expert
`
`09:09:16
`
` witness and I -- in the case for Baxter, Baxter was
`
` the manufacturer that was being sued by patients who
`
` were hurt or damaged by the contaminated Heparin.
`
` Q So this was a products liability --
`
` A Yes, it was.
`
` Q -- issue? Have you ever had any patent
`
` litigation experience or patent --
`
` A Yes.
`
` Q -- experting experience? Can -- can you
`
` describe those.
`
` A Yes, one example was in the case of Teva
`
` and Momenta.
`
` Q And which side did you represent?
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:09:23
`
`09:09:32
`
`09:09:35
`
`09:09:39
`
`09:09:41
`
`09:09:42
`
`09:09:44
`
`09:09:47
`
`09:09:48
`
`09:09:50
`
`09:09:52
`
`09:10:00
`
`09:10:03
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 20
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`20
`
` A I represented Teva.
`
` Q Any other one?
`
` A In -- in --
`
` Q In patent litigation.
`
` A In patent litigation that's ongoing
`
` currently or that, you know --
`
` Q Well, I don't want you to say anything
`
` that's confidential, but all -- I -- all I'm trying
`
` to do is ask your experiences, past experiences, if
`
` you could tell me besides Teva versus Momenta and
`
` then if you could say, yeah, I'm also working with
`
` somebody else now on an ongoing litigation, I mean,
`
` that's fine. I'm just trying to understand.
`
` A Right, so I am also working with somebody
`
` else now on an ongoing litigation.
`
` Q Okay. And then -- but in the past it was
`
` only the Teva case?
`
` A I think that's true, but I might have -- I
`
` know I didn't give a declaration, another declaration
`
` or deposition. I probably would have remembered
`
` that.
`
` Q And the ongoing one that you're involved in
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:10:05
`
`09:10:09
`
`09:10:14
`
`09:10:17
`
`09:10:18
`
`09:10:20
`
`09:10:23
`
`09:10:25
`
`09:10:29
`
`09:10:33
`
`09:10:37
`
`09:10:40
`
`09:10:42
`
`09:10:44
`
`09:10:47
`
`09:10:49
`
`09:10:50
`
`09:10:52
`
`09:10:59
`
`09:11:02
`
`09:11:05
`
`09:11:05
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 21
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`21
`
` is different than -- than this action?
`
` A Yes.
`
` Q Okay. And are there any other products
`
` liability cases that you were involved with besides
`
` the one that you mentioned about Baxter?
`
` A I don't believe so.
`
` Q Do you consider yourself an expert in
`
` immunology?
`
` A I have some expertise in immunology, but I
`
` would not consider myself an expert immunologist.
`
` Q And what I mean by -- by immunology is how
`
` the immune system reacts to the carbohydrate, that's
`
` my definition.
`
` A I would consider that I have some expertise
`
` in immunology, particularly how the immune system
`
` reacts with carbohydrates.
`
` Q But you do not consider yourself an expert,
`
` correct?
`
` A I do not consider myself an expert
`
` immunologist. I do have some expertise in that area.
`
` Q Got it, okay. I'd like to ask you then to
`
` take a look, if you could, please, at your
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:11:07
`
`09:11:08
`
`09:11:09
`
`09:11:12
`
`09:11:14
`
`09:11:17
`
`09:11:21
`
`09:11:24
`
`09:11:29
`
`09:11:32
`
`09:11:35
`
`09:11:39
`
`09:11:43
`
`09:11:44
`
`09:11:46
`
`09:11:50
`
`09:11:53
`
`09:11:57
`
`09:11:57
`
`09:11:59
`
`09:12:03
`
`09:12:05
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 22
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`22
`
` declaration against the '549 patent. The other one
`
` you can put aside because we'll be spending most of
`
` our time with the '549. And I'd like to ask you to
`
` take a look at Paragraph No. 6.
`
` And in this paragraph -- and in this
`
` Paragraph 6 you say, "In my opinion, a POSITA" --
`
` P-O-S-I-T-A -- "would hold at least a bachelor's
`
` level degree in chemistry or biochemistry with some
`
` related post-graduate experience (academic or
`
` industrial) in the area of carbohydrates and their
`
` metal complexes."
`
` Did I read that correctly?
`
` A That's correct.
`
` Q Now, POSITA means, to your understanding,
`
` person of ordinary skill in the art, correct?
`
` A That's my understanding of the term POSITA.
`
` Q And POSITA is a patent term, correct?
`
` A I think so, or a legal term.
`
` Q But it's not a scientific term?
`
` A It's not scientific term.
`
` Q It's not a term that you would use in the
`
` laboratory, basically?
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:12:08
`
`09:12:12
`
`09:12:15
`
`09:12:19
`
`09:12:49
`
`09:12:50
`
`09:12:56
`
`09:13:00
`
`09:13:03
`
`09:13:06
`
`09:13:11
`
`09:13:12
`
`09:13:14
`
`09:13:14
`
`09:13:18
`
`09:13:21
`
`09:13:24
`
`09:13:34
`
`09:13:36
`
`09:13:37
`
`09:13:40
`
`09:13:43
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 23
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
` A Probably not.
`
`23
`
`09:13:47
`
` Q Well, I want to ask you about this -- this
`
`09:13:47
`
` statement a little bit. You say -- you refer to some
`
`09:13:49
`
` related post-graduate experience. What do you mean
`
` by some?
`
` A Well, some is more than none.
`
` Q Okay.
`
` A And -- so it could be a year or two or
`
` three working in an academic or industrial
`
` environment.
`
` Q So what's -- what is your opinion then
`
` about what you meant by -- by this statement about
`
` the minimum? Is one year a minimum to you or how
`
` much? I'm trying to understand.
`
` A So it depends on the -- the area and the
`
` depth of the experience.
`
` Q Okay. So there's -- is there any way to
`
` quantify what you mean by some, it just depends?
`
`09:13:54
`
`09:13:56
`
`09:14:02
`
`09:14:04
`
`09:14:05
`
`09:14:11
`
`09:14:16
`
`09:14:17
`
`09:14:20
`
`09:14:23
`
`09:14:27
`
`09:14:30
`
`09:14:36
`
`09:14:40
`
`09:14:43
`
` A Well, there would be a difference if, say,
`
`09:14:48
`
` the industrial experience was directly related to
`
` making iron carbohydrate complexes. That -- in that
`
` case it might take less time to develop that
`
`09:14:52
`
`09:14:57
`
`09:15:05
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 24
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`24
`
` experience of POSITA than if the experience was in
`
` another area that was not this closely related to the
`
` scope of the '549 patent.
`
` Q Is there any other thing you want to add as
`
` to what you mean by some related experience?
`
` A Some is -- is more than none and it could
`
` be, you know, multiple years, it could be multiple
`
` years in industry or multiple years in academic
`
` experience.
`
` Q Okay. One -- one thing that -- that I
`
` wanted to ask you about is there doesn't seem to be
`
` any upper limit here about what one of ordinary skill
`
` in the art is. So it would seem to include somebody
`
` with some experience and -- and a degree, but also up
`
` to a Nobel Prize professor, and I don't know if -- if
`
` there's in your mind any cutoff between a person of
`
` ordinary skill in the art and one of more than
`
` ordinary skill in the art?
`
` A Okay, well, let's take a Nobel Prize
`
` winner, for example. So if a Nobel Prize winner had
`
` bachelor's level degree in chemistry and won the
`
` Nobel Prize in quantum mechanics but has no
`
`PLANET DEPOS
`888.433.3767 | WWW.PLANETDEPOS.COM
`
`09:15:09
`
`09:15:14
`
`09:15:17
`
`09:15:19
`
`09:15:23
`
`09:15:27
`
`09:15:35
`
`09:15:40
`
`09:15:44
`
`09:15:46
`
`09:15:48
`
`09:15:52
`
`09:15:55
`
`09:15:59
`
`09:16:02
`
`09:16:08
`
`09:16:11
`
`09:16:14
`
`09:16:17
`
`09:16:21
`
`09:16:25
`
`09:16:29
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Luitpold Pharmaceuticals, Inc., Ex. 2056, P. 25
`
`Pharmacosmos A/S v. Luitpold Ex. Pharmaceuticals, Inc., IPR2015-01490
`
`
`
`Videotaped Deposition of Robert Linhardt, Ph.D.
`Conducted on March 2, 2016
`
`25
`
` experience in the realm of carbohydrates or iron or
`
` even the performance of laboratory experiments, I
`
` would say that that wouldn't count as additional
`
` experience making this person a POSA.
`
` Q Okay. So what you're saying is that it
`
` really depends on the individual person, their
`
` qualific